CAS 123039-93-0: Cloridrato di Dihidrexidina

Dihydrexidine is a full efficacy D1-like dopamine receptor (D1/D5) agonist (IC50: 10 nM for D1 receptor). It also shows potent antiparkinsonian activity.

Dihydrexidine is a selective dopamine receptor agonist, which is synthesized in a laboratory setting. It primarily acts on D1-like dopamine receptors, facilitating an increase in dopaminergic signaling pathways. This increased signaling is achieved through binding and activating specific receptor subtypes that influence numerous neural pathways. The mode of action of dihydrexidine involves the modulation of dopaminergic transmission, which can impact various neurological and psychiatric conditions. By selectively targeting D1-like receptors, dihydrexidine has been shown to enhance cognitive processes and motor functions, making it a valuable investigational tool for understanding dopaminergic mechanisms in the brain. The uses and applications of dihydrexidine are centered around its experimental potential in treating disorders involving dopamine dysregulation, such as Parkinson’s disease and schizophrenia. Its selective action provides insights into dopaminergic pathways, contributing to research in neuropharmacology and psychopharmacology. While not yet approved for clinical use, dihydrexidine continues to be a subject of exploration in preclinical studies, offering promise for future therapeutic developments.